MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-13-2026
Exact Sciences Corporation General and Administrative Expenses 2011-2026 | EXAS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Exact Sciences Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 889 M | 782 M | 800 M | 663 M | 801 M | 481 M | 540 M | 296 M | 186 M | 138 M | 106 M | 65.2 M | 22.7 M | 14.4 M | 8.14 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 889 M | 8.14 M | 386 M |
Quarterly General and Administrative Expenses Exact Sciences Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 241 M | 209 M | 221 M | - | 194 M | 178 M | 220 M | - | 217 M | 238 M | 217 M | - | 192 M | 182 M | 170 M | - | 187 M | 168 M | 268 M | - | 116 M | 107 M | 114 M | 144 M | 80.5 M | 63.7 M | 63.8 M | 56.3 M | 46.7 M | 39.5 M | 35.5 M | 33.6 M | 30.8 M | 24.6 M | 20.1 M | 21.5 M | 20.3 M | 17.3 M | 17.8 M | 15.9 M | 15.4 M | 13.7 M | 13 M | 10.6 M | 8.99 M | 6.23 M | 4.59 M | 3.69 M | 3.69 M | 3.63 M | 2.65 M | 2.82 M | 2.55 M | 2.39 M | 2.14 M | 2.21 M | 1.95 M | 1.83 M | 2.15 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 268 M | 1.83 M | 79.1 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
6.63 M | $ 2.86 | -3.38 % | $ 92.8 K |  USA |
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.62 B | $ 118.89 | 0.64 % | $ 36.1 B | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 13.75 | -3.17 % | $ 416 M | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 107.73 | -0.5 % | $ 8.89 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 636.84 | 0.02 % | $ 51.2 B | USA |
 |
Illumina
ILMN
|
1.09 B | $ 130.15 | -2.06 % | $ 20.7 B | USA |
 |
Celcuity
CELC
|
9.06 M | $ 108.05 | -0.24 % | $ 4.26 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
200 M | $ 27.48 | -1.84 % | $ 763 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 283.25 | -1.05 % | $ 23.6 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 79.36 | 4.01 % | $ 5.36 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
743 M | $ 175.2 | -1.93 % | $ 8.68 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 318.91 | -0.31 % | $ 27.2 B |  Schweiz |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
257 M | $ 5.21 | 3.89 % | $ 482 M | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 9.59 | 0.89 % | $ 1.23 B | USA |
 |
Natera
NTRA
|
589 M | $ 208.22 | 4.02 % | $ 20.5 B | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.52 | -6.17 % | $ 456 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Precipio
PRPO
|
9.45 M | $ 24.7 | 0.08 % | $ 32.1 M | USA |
|
Biodesix
BDSX
|
80.5 M | $ 15.67 | -0.51 % | $ 2.03 B | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 6.82 | -17.66 % | $ 285 M | USA |
 |
Sotera Health Company
SHC
|
253 M | $ 15.74 | -1.06 % | $ 4.47 B | USA |
 |
Soleno Therapeutics
SLNO
|
132 M | $ 38.17 | -2.28 % | $ 1.94 B | USA |
 |
BioNano Genomics
BNGO
|
51.9 M | $ 1.12 | -2.19 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 208.58 | -0.79 % | $ 23.2 B | USA |
 |
Danaher Corporation
DHR
|
8.24 B | $ 204.29 | -0.83 % | $ 146 B | USA |
 |
Bioventus
BVS
|
304 M | $ 8.78 | 0.11 % | $ 550 M | USA |
 |
DarioHealth Corp.
DRIO
|
18.1 M | $ 10.3 | -4.19 % | $ 292 M |  Israel |
 |
DexCom
DXCM
|
1.29 B | $ 72.86 | -1.24 % | $ 28.4 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.73 B | $ 507.94 | -0.1 % | $ 191 B | USA |
 |
Twist Bioscience Corporation
TWST
|
247 M | $ 47.14 | 2.72 % | $ 2.82 B | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 24.01 | -6.38 % | $ 254 M | China |
 |
VolitionRx Limited
VNRX
|
8.49 M | $ 0.2 | -2.22 % | $ 19.2 M |  Singapore |
 |
CareDx, Inc
CDNA
|
108 M | $ 18.74 | -0.03 % | $ 999 M | USA |
 |
Waters Corporation
WAT
|
240 M | $ 311.27 | 1.35 % | $ 18.5 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
211 M | $ 94.75 | 2.73 % | $ 11.9 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 173.82 | -0.27 % | $ 29.9 B | USA |